Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment
| Autor: | Guy Jerusalem, Concetta Elisa Onesti, Pierre Frères |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine business.industry Immune checkpoint inhibitors medicine.medical_treatment macromolecular substances Immunotherapy Ligand (biochemistry) Cancer treatment Clinical Practice 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Text mining Editorial Cytotoxic T-Lymphocyte-Associated Antigen 4 030220 oncology & carcinogenesis Cancer research Medicine business Pseudoprogression |
| Popis: | Over the last 5 years, immunotherapy has become one of the backbones for cancer treatment, showing significant improvement in prognosis for several malignancies. Currently, in clinical practice, we have several immune checkpoint inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1), while several other drugs, directed toward different co-inhibitory or co-stimulatory molecules, are under evaluation (1). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|